Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.

Bueno C, Velasco-Hernandez T, Gutiérrez-Agüera F, Zanetti SR, Baroni ML, Sánchez-Martínez D, Molina O, Closa A, Agraz-Doblás A, Marín P, Eyras E, Varela I, Menéndez P.

Leukemia. 2019 Feb 18. doi: 10.1038/s41375-019-0418-8. [Epub ahead of print] No abstract available.

PMID:
30778134
2.

Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions.

Bueno C, Calero-Nieto FJ, Wang X, Valdés-Mas R, Gutiérrez-Agüera F, Roca-Ho H, Ayllon V, Real PJ, Arambilet D, Espinosa L, Torres-Ruiz R, Agraz-Doblas A, Varela I, de Boer J, Bigas A, Gottgens B, Marschalek R, Menendez P.

Haematologica. 2019 Jun;104(6):1189-1201. doi: 10.3324/haematol.2018.202044. Epub 2019 Jan 24.

3.

Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis.

Agraz-Doblas A, Bueno C, Bashford-Rogers R, Roy A, Schneider P, Bardini M, Ballerini P, Cazzaniga G, Moreno T, Revilla C, Gut M, Valsecchi MG, Roberts I, Pieters R, De Lorenzo P, Varela I, Menendez P, Stam RW.

Haematologica. 2019 Jun;104(6):1176-1188. doi: 10.3324/haematol.2018.206375. Epub 2019 Jan 24.

4.

Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR.

Llerena S, García-Díaz N, Curiel-Olmo S, Agraz-Doblas A, García-Blanco A, Pisonero H, Varela M, Santibáñez M, Almaraz C, Cereceda L, Martínez N, Arias-Loste MT, Puente Á, Martín-Ramos L, de Lope CR, Castillo-Suescun F, Cagigas-Fernandez C, Isidro P, Lopez-López C, Lopez-Hoyos M, Llorca J, Agüero J, Crespo-Facorro B, Varela I, Piris MÁ, Crespo J, Vaqué JP.

Oncotarget. 2018 Jul 20;9(56):30869-30882. doi: 10.18632/oncotarget.25766. eCollection 2018 Jul 20.

5.

Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas.

González-Vela MDC, Curiel-Olmo S, Derdak S, Beltran S, Santibañez M, Martínez N, Castillo-Trujillo A, Gut M, Sánchez-Pacheco R, Almaraz C, Cereceda L, Llombart B, Agraz-Doblas A, Revert-Arce J, López Guerrero JA, Mollejo M, Marrón PI, Ortiz-Romero P, Fernandez-Cuesta L, Varela I, Gut I, Cerroni L, Piris MÁ, Vaqué JP.

J Invest Dermatol. 2017 Jan;137(1):197-206. doi: 10.1016/j.jid.2016.08.015. Epub 2016 Sep 1.

6.

Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency.

Muñoz-López A, Romero-Moya D, Prieto C, Ramos-Mejía V, Agraz-Doblas A, Varela I, Buschbeck M, Palau A, Carvajal-Vergara X, Giorgetti A, Ford A, Lako M, Granada I, Ruiz-Xivillé N, Rodríguez-Perales S, Torres-Ruíz R, Stam RW, Fuster JL, Fraga MF, Nakanishi M, Cazzaniga G, Bardini M, Cobo I, Bayon GF, Fernandez AF, Bueno C, Menendez P.

Stem Cell Reports. 2016 Oct 11;7(4):602-618. doi: 10.1016/j.stemcr.2016.08.013. Epub 2016 Sep 22.

7.

Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia.

Prieto C, Stam RW, Agraz-Doblas A, Ballerini P, Camos M, Castaño J, Marschalek R, Bursen A, Varela I, Bueno C, Menendez P.

Cancer Res. 2016 Apr 15;76(8):2478-89. doi: 10.1158/0008-5472.CAN-15-2769. Epub 2016 Feb 2.

Supplemental Content

Loading ...
Support Center